Question 1

What type of variation is “Change in the batch size (including batch size ranges) of the finished product” under the SFDA Guidelines for Variation Requirements?

Accepted Answer

SFDA Guidelines for Variation Requirements v6.3, item 29 (II.2 Finished product b) Manufacture): a) Up to 10-fold compared to the currently approved batch size. — Type IA(IN); b) Downscaling down to 10-fold. — Type IA; c) The change relates to a biological/immunological medicinal product or the change in batch size requires a new bioequivalence study. — Type II; d) The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes — Type II; e) More than 10-fold increase compared to the currently approved batch size for immediate release (oral) pharmaceutical forms. — Type IB; f) The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) — Type IB; g) Product that was exempted from the biobatch requirements (1/10 of production scale or 100,000 units, whichever is greater) because of the small production scale. — Type II.

Question 2

How is “Change in the batch size (including batch size ranges) of the finished product” classified in the EU?

Accepted Answer

Commission Guidelines C/2025/5045: Q.II.b.4 Change in the batch size (including batch size ranges) of the finished product: a) Up to 10-fold increase compared to the originally approved batch size — Type IA; b) Downscaling down to 10-fold — Type IA; c) The change requires assessment of the comparability of a biological finished product or the change in batch size requires a new bioequivalence study — Type II; d) The change relates to all other pharmaceutical forms manufactured by novel or complex manufacturing processes — Type II; e) More than 10-fold increase/decrease compared to the originally approved batch size — Type IB; f) The scale for a biological finished product is increased/decreased without process change (e.g. duplication of line) — Type IB

Question 3

How is “Change in the batch size (including batch size ranges) of the finished product” reported to the US FDA?

Accepted Answer

21 CFR 314.70 and FDA guidance: Scale-up or scale-down (no fold limit) with equipment of the same design and operating principle; not natural-protein products — Annual report (2014 App. B 3.1; 2004 §VII.D.1); Natural-protein product: finishing-step scale change without equipment change; adding identical parallel processing lines — Annual report (2004 §VII.D.7; 2014 App. A 3.4); Scale change needing equipment of a different design/principle (incl. natural-protein finishing steps); terminally sterilized scale-up extending bulk hold by more than 50% — CBE-30 supplement (2004 §VII.C.1.c, §VII.C.1.a, §VII.C.1.d; 21 CFR 314.70(c)(2)(ii)(A)); Scale change requiring a new in vivo BE study, affecting modified release/metering, or extending aseptic processing time more than 50% beyond validated limits — Prior approval supplement (2004 §XI.A.1, §VII.B.1–2; 21 CFR 314.70(b)(2)(ii)). FDA sets no fold limit on scale: the 2004 guidance superseded the SUPAC scale levels for reporting category (§I), though SUPAC data recommendations (dissolution, stability) still apply. Combining previously separate in-process batches is also AR (2014 App. A 3.2).

Change in the batch size (including batch size ranges) of the finished product

SFDA Saudi Food and Drug Authority

EU European Union

Q.II.b.4 · Change in the batch size (including batch size ranges) of the finished product

US FDA US Food and Drug Administration

Other items in II.2 Finished product b) Manufacture

Variant	Change	Type
a	Up to 10-fold compared to the currently approved batch size.	Type IA(IN)
b	Downscaling down to 10-fold.	Type IA
c	The change relates to a biological/immunological medicinal product or the change in batch size requires a new bioequivalence study.	Type II
d	The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes	Type II
e	More than 10-fold increase compared to the currently approved batch size for immediate release (oral) pharmaceutical forms.	Type IB
f	The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)	Type IB
g	Product that was exempted from the biobatch requirements (1/10 of production scale or 100,000 units, whichever is greater) because of the small production scale.	Type II

Variant	Change	Type
a	Up to 10-fold increase compared to the originally approved batch size	Type IA
b	Downscaling down to 10-fold	Type IA
c	The change requires assessment of the comparability of a biological finished product or the change in batch size requires a new bioequivalence study	Type II
d	The change relates to all other pharmaceutical forms manufactured by novel or complex manufacturing processes	Type II
e	More than 10-fold increase/decrease compared to the originally approved batch size	Type IB
f	The scale for a biological finished product is increased/decreased without process change (e.g. duplication of line)	Type IB

Change	Category	Reference
Scale-up or scale-down (no fold limit) with equipment of the same design and operating principle; not natural-protein products	Annual report	2014 App. B 3.1; 2004 §VII.D.1
Natural-protein product: finishing-step scale change without equipment change; adding identical parallel processing lines	Annual report	2004 §VII.D.7; 2014 App. A 3.4
Scale change needing equipment of a different design/principle (incl. natural-protein finishing steps); terminally sterilized scale-up extending bulk hold by more than 50%	CBE-30 supplement	2004 §VII.C.1.c, §VII.C.1.a, §VII.C.1.d; 21 CFR 314.70(c)(2)(ii)(A)
Scale change requiring a new in vivo BE study, affecting modified release/metering, or extending aseptic processing time more than 50% beyond validated limits	Prior approval supplement	2004 §XI.A.1, §VII.B.1–2; 21 CFR 314.70(b)(2)(ii)